Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · Jul 2014
Multicenter StudyAssociation of center volume with outcomes in critically ill children with acute asthma.
Little is known about the relation between center volume and outcomes in children requiring intensive care unit (ICU) admission for acute asthma. ⋯ In children with acute asthma, this study establishes a relation between center volume and ICU length of stay. However, this study fails to show any significant relation between center volume and the odds of receiving positive pressure ventilation; further analyses are needed to evaluate this relation in more detail.
-
Ann. Allergy Asthma Immunol. · Nov 2012
Randomized Controlled Trial Multicenter StudyOnce-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.
Fluticasone furoate (FF) is an inhaled corticosteroid (ICS) with 24-hour activity in development as a once-daily treatment for the long-term management of asthma. ⋯ FF 100 to 400 μg once daily in the evening is effective and well tolerated in patients with asthma uncontrolled on low-dose ICS, with 100 μg and 200 μg, considered the most applicable doses in this asthma population.
-
Ann. Allergy Asthma Immunol. · Jan 2012
Multicenter Study Clinical TrialNanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial.
Hereditary angioedema (HAE) is a rare disease caused by C1INH gene mutations, which leads to a deficiency or dysfunction of C1 inhibitor (C1 INH), resulting in recurrent episodes of severe and potentially life-threatening edema. ⋯ This open-label study demonstrates the efficacy and safety of C1 INH-nf for short-term treatment of HAE attacks.
-
Ann. Allergy Asthma Immunol. · Jan 2012
Randomized Controlled Trial Multicenter StudyEvaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.
The Urticaria Activity Score (UAS) is a widely used patient-reported outcome measure for patients with chronic idiopathic urticaria (CIU) that includes 2 items: intensity of pruritus and number of hives. Items are scored individually, and the UAS7 is calculated as the sum of pruritus and number of hives over 1 week. Recently, its instructions were enhanced. ⋯ The enhanced UAS has adequate measurement properties to support its use in clinical research.
-
Ann. Allergy Asthma Immunol. · Dec 2011
Randomized Controlled Trial Multicenter StudyRandomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
The For Angioedema Subcutaneous Treatment (FAST)-3 study was a phase III, randomized, double-blind, placebo-controlled study of icatibant (bradykinin B(2) receptor antagonist) in subjects with hereditary angioedema (HAE) resulting from C1-INH deficiency or dysfunction (type I/II). ⋯ FAST-3 demonstrated that icatibant was effective and generally well tolerated in subjects with acute HAE attacks.